ASCO® GI 2024 Insights: "LIBRETTO-001 Study - Durable Efficacy of Selpercatinib in Patients With RET Fusion+ Solid Tumors (Focus on GI Tumors)"

31 views
March 5, 2024
0 Comments
Login to view comments. Click here to Login